pocketful logo
Alembic Ltd logo

Alembic Ltd

NSE: ALEMBICLTD BSE: 506235

₹91.72

(0.64%)

Wed, 04 Mar 2026, 11:27 am

mtf coin illustrationMTF 5x

Alembic Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    2288.70

  • Net Profit

    144.57

  • P/B

    1.08

  • Sector P/E

    32.94

  • P/E

    8.14

  • EV/EBITDA

    15.06

  • Debt/Equity (Industry)

    1.17

  • Interest Cover (Industry)

    1.89

  • ROCE (Industry)

    6.03

  • RONW (Industry)

    4.86

  • ROE

    6.39

  • ROCE

    6.90

  • Debt/Equity

    0.01

  • EPS (TTM)

    12.41

  • Dividend Yield

    2.69

  • Book Value

    98.75

  • Interest Cover

    63.96

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (21.4x coverage).
  • Alembic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alembic is profitable, therefore cash runway is not a concern.
  • Alembic is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Alembic's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Alembic's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Alembic is not covered by any analysts.
  • Alembic has significant price volatility in the past 3 months.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters70.8870.8870.8870.8870.88
FII1.281.371.501.651.78
DII0.050.050.050.050.06
Public27.7927.6927.5727.4227.28
Government00000

Read More

Technical Analysis

RSI

27.07

MACD

-1.88

50 DMA

96.16

200 DMA

104.33

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic116.10105.1398.4394.1687.4683.1972.22
Fibonacci105.13100.9498.3594.1689.9787.3883.19
Camarilla94.7493.7392.7394.1690.7189.7188.70

Pivots Level: Classic

R3

+21.94

116.10

R2

+10.97

105.13

R1

+4.26

98.43

94.16
94.16
Pivot Point
LTP: 86.30

S1

-6.71

87.46

S2

-10.97

83.19

S3

-21.94

72.22

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    91.41

  • 20-EMA

    93.15

  • 30-EMA

    94.14

  • 50-EMA

    95.54

  • 100-EMA

    98.21

  • 200-EMA

    102.28

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 Feb 2026board-meetingsQuarterly Results, Nine Months Results
10 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
05 Jul 2025dividendFinal Dividend - Rs. - 2.405 Aug 2025
04 Jul 2025agm
13 May 2025dividend₹2.40 Dividend /Share05 Aug 2025
05 Jul 2024dividendFinal Dividend - Rs. - 2.405 Aug 2024
14 Jun 2024agm
13 May 2024dividend₹2.40 Dividend /Share05 Aug 2024
03 Jul 2023dividendFinal Dividend - Rs. - 2.203 Aug 2023
20 Jun 2023agm

Read More

Peer Comparison

Alembic Ltd logo

Alembic Ltd

Oberoi Realty Ltd logo

Oberoi Realty Ltd

DLF Ltd logo

DLF Ltd

Lodha Developers Ltd logo

Lodha Developers Ltd

Phoenix Mills Ltd logo

Phoenix Mills Ltd

Prestige Estates Projects Ltd logo

Prestige Estates Projects Ltd

Read More

Alembic Ltd About

Alembic is dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.

Industry

Construction

Founded

1907

Headquarters

CEO

Chirayu R Amin

Employees

Contact

Website icon

Website

http://www.alembiclimited.com

Email icon

Email

alembic.investors@alembic.co.in

Phone icon

Phone

91-0265-2280550

Location icon

Location

Alembic Road, , Vadodara, Gujarat, 390003

Read More

Alembic Ltd Company History

YearHistory
2012
  • Appointed Chandrashekhar P. Buch as Additional Non-Executive Independent Director.
2013
  • Allotted 13,35,15,914 bonus equity shares in 1:1 ratio.
  • Appointed R. C. Saxena as Additional Non-Executive Independent Director.
  • Recommended dividend of Re. 0.20 (10%) per equity share of Rs. 2.
2014
  • Recommended dividend of Re. 0.15 (7.5%) per equity share of Rs. 2.
2018
  • HGS won NASSCOM Customer Service Excellence Award 2018 in Transformation Category.
2020
  • Received USFDA approval for generic ophthalmic solution.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPBuy136688998.1314 May 2024
GRAVITON RESEARCH CAPITAL LLPSell136688998.2114 May 2024
CRONY VYAPAR PVT LTDSell174510782.7630 Oct 2023
CRONY VYAPAR PVT LTDBuy182080982.6830 Oct 2023
CRONY VYAPAR PVT LTDBuy125995281.1427 Oct 2023
CRONY VYAPAR PVT LTDSell130995281.1927 Oct 2023
CRONY VYAPAR PVT LTDBuy181873278.4526 Oct 2023
GRAVITON RESEARCH CAPITAL LLPBuy132633478.2726 Oct 2023
GRAVITON RESEARCH CAPITAL LLPSell132633478.1226 Oct 2023
CRONY VYAPAR PVT LTDSell168970878.3726 Oct 2023

Read More

Alembic Ltd News

Alembic Gets USFDA Approval for Parkinson's Drug

Alembic Pharmaceuticals receives USFDA final approval for Carbidopa, Levodopa and Entacapone tablets, therapeutically equivalent to Stalevo, bringing total ANDA approvals to 234.

06 Feb 2026

stocks

Alembic Pharma Q3 Net Profit Drops to ₹1.33B

Alembic Pharmaceuticals reports consolidated net profit of ₹1.33 billion in Q3, down from ₹1.40 billion in the same quarter previous year, marking a year-over-year decline.

05 Feb 2026

co actions results

Alembic Gets USFDA Approval for Eye Drug Generic

Alembic Pharmaceuticals receives USFDA final approval for Difluprednate Ophthalmic Emulsion, 0.05%, generic equivalent to Durezol. Company now has 233 total ANDA approvals from USFDA.

27 Jan 2026

stocks

Alembic Pharma gets USFDA tentative approval for cancer drug

Alembic Pharmaceuticals receives tentative USFDA approval for Bosutinib Tablets 400mg, used in treating chronic myelogenous leukemia. The drug has an estimated US market size of $251 million.

12 Jan 2026

stocks

Alembic Gets USFDA Approval for Bosutinib Tablets

Alembic Pharmaceuticals receives USFDA tentative approval for 400 mg Bosutinib tablets, generic version of Bosulif, targeting US$ 251 million market by September 2025.

12 Jan 2026

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800